PRTG — Portage Biotech Balance Sheet
0.000.00%
Last trade - 00:00- $13.90m
- $11.47m
- 44
- 35
- 79
- 52
Annual balance sheet for Portage Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3.22 | 2.77 | 23.4 | 10.5 | 5.03 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.56 | 0.683 | 0.351 | 0.801 | 0.103 |
| Prepaid Expenses | |||||
| Total Current Assets | 3.79 | 4.95 | 24.8 | 13.7 | 7.7 |
| Net Property, Plant And Equipment | — | — | — | — | 0.035 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 173 | 175 | 195 | 99.1 | 7.78 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.57 | 3.21 | 0.783 | 1.86 | 2.88 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 76.6 | 73.4 | 73.5 | 23.1 | 3.76 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 96.5 | 101 | 121 | 76 | 4.02 |
| Total Liabilities & Shareholders' Equity | 173 | 175 | 195 | 99.1 | 7.78 |
| Total Common Shares Outstanding |